Foundation Medicine, Ophthotech Enjoy First-Day IPO Pops
This article was originally published in The Pink Sheet Daily
The flood of new listings continued unabated, as a trio of offerings followed three successful IPOs last week. Cancer diagnostics start-up Foundation Medicine and “wet” AMD therapy developer Ophthotech outperformed expectations, pricing above their ranges and selling more shares than anticipated.
You may also be interested in...
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
ARCH Venture Partners joined original investor Third Rock Ventures in backing the Cambridge, Mass., start-up with $20 million in Series B money. SAGE is concentrating its efforts on several compounds, including one to treat a type of epileptic seizure, which could represent the beginning of a larger epilepsy franchise.
After a slow August and early September, Wall Street is preparing for four biotech IPOs. Biotech IPOs have been on fire, outperforming even the vigorous biotech indices. But the question remains – can public investors get too much of a good thing?